LYRA insider buying and SEC filings, explained
Lyra Therapeutics, Inc. · CIK 1327273
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$527K
Planned sales (10b5-1)
$8K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Jan 6, 2026 | Planned (10b5-1) | Jason Cavalier (CFO) sold 769 shares at $3.36 ($3K), marked as a 10b5-1 plan trade. Holdings down <1% to 518,547 shares. | SEC filing Filed Jan 8, 2026 |
| Jan 6, 2026 | Planned (10b5-1) | Maria Palasis (CEO and Director) sold 1,702 shares at $3.36 ($6K), marked as a 10b5-1 plan trade. Holdings down <1% to 1,096,733 shares. | SEC filing Filed Jan 8, 2026 |
| Nov 11–13, 2025 | Sale | Joseph Edelman (10% owner) sold 45,875 shares indirectly between Nov 11, 2025 and Nov 13, 2025 at about $3.98 ($182K). Indirect holdings down 77% to 14,026 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 3 other reporting owners. | SEC filing Filed Nov 13, 2025 |
| Nov 6–10, 2025 | Sale | Joseph Edelman (10% owner) sold 70,390 shares indirectly between Nov 6, 2025 and Nov 10, 2025 at about $4.89 ($344K). Indirect holdings down 79% to 18,659 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 3 other reporting owners. | SEC filing Filed Nov 10, 2025 |
3 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow LYRA in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.